RIPK1-IN-32
RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis.
For research use only. We do not sell to patients.
- Formula: C42H59NO7S2
- Molecular Weight:754.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
NF-κB |
IL-6 |
RIPK1 |
RIPK1-IN-32 (Compound 12) (0-25 μM, 45-63 °C) significantly inhibits the thermal degradation of RIPK1 in RAW264.7 macrophages[1].
RIPK1-IN-32 (2.5 μM) significantly diminishes p65 and c-fos nuclear translocation in RAW264.7 macrophages[1].
RIPK1-IN-32 (0.625-2.5 μM, 8 h) notably reduces d the levels of IL-6 and TNF-α in RAW 264.7 cells[1].
RIPK1-IN-32 (0.625-2.5 μM, 8 h) effectively hinders the LPS (HY-D1056B3)-induced activation of the RIPK1/NF-κB/MAPK pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LPS-stimulated RAW 264.7 macrophages
-
Concentration:0.625, 1.25, 2.5 μM
-
Incubation Time:8 h, including 1 μg/mL LPS for 6 hours
-
Result:Significantly diminished the contents of IL-6 and TNF-α.
-
Cell Line:LPS-stimulated RAW 264.7 macrophages
-
Concentration:0.625, 1.25, 2.5 μM
-
Incubation Time:8 h, including 1 μg/mL LPS for 6 hours
-
Result:Resulted in notable decreases in the levels of RIPK1, p-p65, and p-IκB suggesting an inhibition of NF-κB signaling.
Found to lower the protein levels of p-p38, p-ERK, and p-JNK which aligns with the suppression of MAPK signaling.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS injection into the tail vein to create a sepsis model established in Male BALB/c mice (18-20 g)[1]
-
Dosage:1.25, 2.5 and 5 mg/kg
-
Administration:Intravenous injection (i.v.), single dose
-
Result:Markedly alleviated LPS-induced ALI.
Decreased the serum levels of ALT and AST.
Significantly diminished the contents of IL-6 and TNF-α.
Attenuated the damage to lung tissue and markedly lessened the pathological alterations noted in the kidneys subsequent.
Decreased in liver concentrations of RIPK1, p-p65, P-IκB, p-p38, p-ERK, and p-JNK.
Chemical Information
-
Molecular Weight 754.05
-
Formula C42H59NO7S2
-
SMILES
[H][C@@]12CC[C@@]([C@]3(C)[C@@](C4=C(C(O[C@H]4C3)=O)CC/C=C(C)/C)([H])C[C@H]5O)(C)[C@@]5([C@]1(CC[C@H]([C@H]2C)OC(CCSSCCC(NOCC6=CC=CC=C6)=O)=O)C)[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz